Stefania Napolitano, Aparna R Parikh, Jason Henry, Christine M Parseghian, Jason Willis, Kanwal P Raghav, Van K Morris, Benny Johnson, Bryan K Kee, Arvind N Dasari, Michael J Overman, Raja Luthra, Leylah M Drusbosky, Ryan B Corcoran, Scott Kopetz, Ryan Sun
PURPOSE: In metastatic colorectal cancer, the detection of RAS mutations by circulating tumor DNA (ctDNA) has emerged as a valid and noninvasive alternative approach to determining RAS status. However, some RAS mutations may be missed, that is, false negatives can occur, possibly compromising important treatment decisions. We propose a statistical model to assess the probability of false negatives when performing ctDNA testing for RAS. METHODS: Cohorts of 172 subjects with tissue and multipanel ctDNA testing from MD Anderson Cancer Center and 146 subjects from Massachusetts General Hospital were collected...
September 2023: JCO Precision Oncology